Imatinib Farmalider (Imatinib)

Imatinib acts on malignant cells driven by BCR‑ABL, c‑KIT or PDGFR tyrosine kinase signaling.

• Chronic myeloid leukemia (CML): reduces leukemic cell proliferation and induces remission.
• Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): improves survival by targeting BCR‑ABL‑positive blasts.
• Gastrointestinal stromal tumor (GIST): inhibits c‑KIT driven tumor growth, leading to disease control.

• Imatinib selectively inhibits the ATP‑binding sites of BCR‑ABL, c‑KIT and platelet‑derived growth factor receptor (PDGFR) tyrosine kinases. By blocking these enzymes, it prevents downstream phosphorylation cascades that drive cell proliferation, survival and angiogenesis, thereby suppressing the growth of malignant clones that depend on these pathways. The inhibition is competitive and reversible, leading to sustained suppression of oncogenic signaling while sparing normal cells that lack the activated kinases.

Imatinib may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Diarrhea: loose stools, often transient.
• Edema: peripheral swelling, especially of the ankles.
• Fatigue: generalized tiredness.
• Muscle cramps: occasional involuntary contractions.
• Rash: mild skin eruptions.

Serious or Rare Side Effects

• Hepatotoxicity: elevated liver enzymes or liver injury.
• Cardiotoxicity: decreased left ventricular ejection fraction or heart failure.
• Severe neutropenia: marked reduction in white blood cells.
• Thromboembolic events: deep vein thrombosis or pulmonary embolism.
• Anaphylaxis: acute allergic reaction requiring emergency care.

When prescribing Imatinib, clinicians should consider several precautionary measures to ensure patient safety.

• Baseline assessment: obtain complete blood count, liver function tests and renal function before initiation.
• Cardiac monitoring: evaluate cardiac function in patients with pre‑existing heart disease.
• Drug interactions: review concomitant medications that affect CYP3A4 metabolism.
• Pregnancy and lactation: avoid use unless benefits outweigh potential risks, as safety data are limited.
• Infection risk: monitor for signs of infection due to possible neutropenia.
• Store at ambient temperature: keep below 25 °C in the original packaging, protected from moisture and light.

Imatinib interacts with several medicines that can alter its plasma concentration or increase toxicity.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): markedly reduce imatinib exposure.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase imatinib levels and risk of adverse effects.

Moderate Interactions (Monitor Closely)

• Acid‑reducing agents (e.g., proton pump inhibitors, antacids): may decrease imatinib absorption.
• Anticoagulants (e.g., warfarin): imatinib can enhance anticoagulant effect, requiring INR monitoring.
• Vaccines (live attenuated): potential reduced efficacy; consider timing of administration.